111 related articles for article (PubMed ID: 9007851)
1. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine.
Miyoshi K; Miyake H; Ichihara K; Kamei H; Nagasaka M
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):119-25. PubMed ID: 9007851
[TBL] [Abstract][Full Text] [Related]
2. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blocking and vasodilating actions of the novel dihydropyridine derivative AE0047.
Nishikawa M; Gohda M; Shinyama H; Matzno S; Yamanaga K; Kido H; Nakamura N
Clin Exp Pharmacol Physiol; 1998 May; 25(5):347-54. PubMed ID: 9612662
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats.
Ichihara K; Okumura K; Kamei H; Nagasaka M; Kanda A; Kanno T; Miyoshi K; Miyake H
J Cardiovasc Pharmacol; 1998 Feb; 31(2):277-85. PubMed ID: 9475270
[TBL] [Abstract][Full Text] [Related]
5. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
[TBL] [Abstract][Full Text] [Related]
6. Selective cardiodepressant activity of fluodipine, a fluorenone-1,4-dihydropyridine derivative.
Budriesi R; Aicardi G; Campana G; Spampinato S; Zaza A; Bisi A; Rampa A; Valenti P; Chiarini A
Eur J Pharmacol; 1998 Oct; 359(2-3):161-70. PubMed ID: 9832387
[TBL] [Abstract][Full Text] [Related]
7. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
Jpn J Pharmacol; 1991 Nov; 57(3):337-48. PubMed ID: 1667534
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
9. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of T-type and L-type Ca(2+) currents by aranidipine, a novel dihydropyridine Ca(2+) antagonist.
Masumiya H; Tanaka Y; Tanaka H; Shigenobu K
Pharmacology; 2000 Aug; 61(2):57-61. PubMed ID: 10940777
[TBL] [Abstract][Full Text] [Related]
11. The interaction of phenylalkylamine calcium channel blockers with the 1,4-dihydropyridine binding site.
Zobrist RH; Giacomini KM; Nelson WL; Giacomini JC
J Mol Cell Cardiol; 1986 Sep; 18(9):963-74. PubMed ID: 3783730
[TBL] [Abstract][Full Text] [Related]
12. MDL 72567, a dihydropyridine calcium-antagonist, that causes vasodilation and direct sinus bradycardia.
Spedding M; DiFrancesco GF; Mir AK; Petty MA; Berg C; Gittos M
J Cardiovasc Pharmacol; 1987 Jul; 10(1):62-71. PubMed ID: 2441155
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity.
Shibata S; Satake N; Kodama I; Hester RK; Wang CG; Jino H; Hojo M; Tatsumi H; Gandhi V; Jones DJ
Eur J Pharmacol; 1991 Oct; 203(3):337-44. PubMed ID: 1773820
[TBL] [Abstract][Full Text] [Related]
14. The effects of strychnine on the regulation of voltage-dependent calcium channels by dihydropyridines in brain and heart.
O'Neill SK; Bolger GT
Pharmacol Biochem Behav; 1990 Apr; 35(4):833-40. PubMed ID: 1693213
[TBL] [Abstract][Full Text] [Related]
15. Effects of aranidipine, a novel calcium channel blocker, on mechanical responses of the isolated rat portal vein: comparison with typical calcium channel blockers and potassium channel openers.
Okumura K; Ichihara K; Nagasaka M
J Cardiovasc Pharmacol; 1997 Feb; 29(2):209-15. PubMed ID: 9057070
[TBL] [Abstract][Full Text] [Related]
16. High-affinity antibodies to the 1,4-dihydropyridine Ca2+-channel blockers.
Campbell KP; Sharp A; Strom M; Kahl SD
Proc Natl Acad Sci U S A; 1986 May; 83(9):2792-6. PubMed ID: 3010317
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of 2,6-dimethyl-3,5-dicarbomethoxy-4-(2-isothiocyano)phenyl-1,4- dihydropy ridine as a Ca2+ channel antagonist.
Gengo P; Su CM; Yousif FB; Triggle DJ
Can J Physiol Pharmacol; 1987 Dec; 65(12):2472-82. PubMed ID: 3449204
[TBL] [Abstract][Full Text] [Related]
18. [Vasodilator effects of LF 2.0254, a new 1,4-dihydropyridine. Comparison with nifedipine].
Pruneau D; Roy F; Brown NL
Therapie; 1989; 44(3):203-8. PubMed ID: 2781506
[TBL] [Abstract][Full Text] [Related]
19. Voltage-dependent binding of 1,4-dihydropyridine Ca2+ channel antagonists and activators in cultured neonatal rat ventricular myocytes.
Wei XY; Rutledge A; Triggle DJ
Mol Pharmacol; 1989 Apr; 35(4):541-52. PubMed ID: 2539561
[TBL] [Abstract][Full Text] [Related]
20. Binding properties of (+/-)[3H]benidipine hydrochloride to rat heart membranes.
Ishii A; Toyama J
J Cardiovasc Pharmacol; 1993 Feb; 21(2):191-6. PubMed ID: 7679151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
